Information Provided By: 
Fly News Breaks for August 3, 2015
LXRX
Aug 3, 2015 | 10:59 EDT
Wedbush analyst Liana Moussatos raised her price target for Lexicon Pharmaceuticals to $19 from $17 after the company said telotristat etiprate met the primary endpoint of its Phase 3 trial in cancer patients with Carcinoid syndrome. The trial results were "impressive and transforming," Moussatos tells investors in a research note. She reiterates an Outperform rating on the stock saying worldwide sales could hit over $550M after launch in early 2017.
News For LXRX From the Last 2 Days
There are no results for your query LXRX
